Demand for GLP-1 drugs surges for weight loss despite initial diabetes focus, with a 700% increase in non-diabetic use in the US since 2019. Market projected to reach $180 billion by 2034, with Novo and Eli Lilly currently leading. Pfizer re-enters obesity drug race after acquiring Metsera. Roche stands out with multiple obesity candidates. Novo and Lilly face legal risks over adverse effects. Novo and Lilly agree to offer obesity drugs at discounted prices. Pfizer, Roche, and Novo top choices among GLP-1 drug manufacturers. Future market entrants expected between 2027 and 2032, with Roche leading the pack. Novo screens as most attractive among current leaders based on valuation and ESG risk. GLP-1 prices expected to fall due to regulatory pressures and competition, with enhanced safety profiles anticipated. Investors advised to navigate ESG risks in the evolving GLP-1 drug market.

Read more at Morningstar: 2 Companies Poised to Capitalize on the Rise of GLP-1 Weight Loss Drugs